Development and release mechanism of diltiazem HCl prolonged release matrix tablets

Drug Delivery

Volumn 16, Issue 2, 2009, Pages 67-74

  Boyapally, Harikrishna ^a   Nukala, Ravi Kumar ^a   Douroumis, Dionysios ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Diltiazem hydrochloride; Direct compression; Higuchi model; Matrix tablets; Sustained release

Indexed keywords

DILTIAZEM; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MICROCRYSTALLINE CELLULOSE; POLYMER;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MIXTURE; DRUG STABILITY; HYDROPHILICITY; HYDROPHOBICITY; MATRIX TABLET; PRIORITY JOURNAL; TABLET COMPRESSION; TABLET FORMULATION;

ACRYLIC RESINS; BIOLOGICAL AVAILABILITY; CELLULOSE; DELAYED-ACTION PREPARATIONS; DILTIAZEM; DRUG STABILITY; HYDROPHOBICITY; KINETICS; LACTOSE; METHACRYLATES; METHYLCELLULOSE; MICROSCOPY, ELECTRON, SCANNING; MODELS, CHEMICAL; POLYMERS; TABLETS;

EID: 62249192187     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802586220     Document Type: Article

References (45)

1. Diez-Pena E, Frutos P, Frutos G, Quijada-Garrido I, Barrales-Rienda JM (2004). The influence of the copolymer composition on the diltiazem hydrochloride release from a series of pH-sensitive poly[(N-isopropylacrylamide) -co-(methacrylic acid)] hydrogels. AAPS Pharm Sci Tech, 20, E33.
2. Korhonen O, Kanerva H, Vidgren M, Urti A, Ketolainen J (2004). Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. J Contr Rel, 95, 515-20.
3. Toti US, Aminabhavi TM (2004). Modified guar gum matrix tablet for controlled release of diltiazem hydrochloride, J Contr Rel, 95, 567-77.
4. Al-Saidan SM, Krishnaiah YSR, Patro SS, Satyanaryana V (2005). In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride, AAPS Pharm Sci Tech, 6, E14-21.
5. Conti S, Maggi L, Segale L, Machiste EO, Conte U, Grenier P, Vergnault G (2007). Matrices containing NaCMC and HPMC 2. Swelling and release mechanism study, Int J Pharm, 333, 143-51.
6. Tanaka Y, Miyazaki Y, Yakou S, Takayama K (2007). Sustained release of highly water-soluble drugs with micelle forming ability from polyionic matrix tablets, Pharmazie, 62, 41-5.
7. Parojcic J, Duric Z, Jovanovic M, Ibric S (2004). An investigation into the factors influencing drug release from hydrophilic matrix tablets based on novel carbomer polymers, Drug Deliv, 11, 59-65.
8. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA (1983). Mechanism of solute release from porous hydrophilic polymers, Int J Pharm, 15, 25-35.
9. Boniferoni MC, Rossi S, Ferrari F, Bartoni M, Caramella C (1995). Influence of medium on dissolution-erosion behavior of Na-carboxymethylcellulose and on viscoelastic properties of gels, Int J Pharm, 117, 41-8.
10. Tapia C, Escobar Z, Costa E, Sapag-Hagar J, Valenzuela F, Basualto C, Gai MN, Yazdani-Pedram M (2004). Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems, Eur J Pharm Biopharm, 57, 65-75.
11. Varshosaz J, Tavakoli N, Ali Eram S (2006). Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets, Drug Del, 13, 113-9.
12. Vargas CI, Ghaly ES (1999). Kinetic release of theophylline from hydrophilic swellable matrices, Drug Dev Ind Pharm, 25, 1045-50.
13. Ranga Rao KV, Devi KP (1989). Swelling controlled release systems: recent developments and applications, Int J Pharm, 48, 1-13.
14. Sanchez-Lafuente C, Faucci MT, Fernandez-Arevalo M, Alvarez-Fuentes J, Rabasco AM, Mura P (2002). Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers, Int J Pharm, 234, 213-21.
15. Velasco MV, Ford JL, Rowe P, Rajabi-Siahboomi AR (1999). Influence of drug:hydroxypropyl methylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC matrices, J Contr Rel, 57, 75-85.
16. Heng PWS, Chan LW, Easterbrook MG, Li X (2001). Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets, J Contr Rel, 76, 39-49.
17. Vatsaraj N, Zia H, Needham T (2002). Formulation and optimization of a sustained-release tablet of ketorolac tromethamine, Drug Del, 9, 153-9.
18. Nair A, Gupta R, Sutrave V (2007). In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product, Pharm Dev Tech, 12, 621-5.
19. Hiremath PS, Saha RN (2008). Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release, Drug Del, 15, 159-68.
20. Katzhendler I, Mader K, Friedman M (2000). Structure and hydration properties of hydroxypropyl methylcellulose matrices containing naproxen and naproxen sodium, Int J Pharm, 200, 161-79.
21. Rodriguez L, Caputo O, Cini M, Cavallari C, Grecchi R (1993). In vitro release of theophylline from directly-compressed matrices containing methacrylic acid copolymers and/or dicalcium phosphate dehydrate, Farmaco, 48, 1597-604.
22. Vercammen JP, Dauwe D, Brioen P (1997). Possibility of use of Eudragit RS as a sustained release matrix agent for the incorporation of water soluble active compounds at high percentages, STP Pharma Sci, 7, 491-7.
23. Liu J, Zhang F, McGinity JW (2001). Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion, Eur J Pharm Biopharm, 52, 181-90.
24. Makhija SN, Vavia PR (2002). Once daily sustained release tablets of venlafaxine, a novel antidepressant, Eur J Pharm Biopharm, 54, 9-15.
25. Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P (2005). Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets, Il Farmaco, 60, 913-8.
26. Patra CN, Kumar AB, Pandit HK, Singh SP, Devi MV (2007). Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride, Acta Pharm, 57, 479-89.
27. Pather I, Russell I, Syce JA, Neau SH (1998). Sustained release theophylline tablets by direct compression, Part 1: formulation and in vitro testing, Int J Pharm, 164, 1-10,
28. Reddy KR, Mutalik S, Reddy S (2003). Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation, AAPS Pharm Sci Tech, 4, 1-9,
29. McGinity JW (1997). Aqueous polymeric coatings for pharmaceutical dosage forms, 2nd ed. New York, Marcel Dekker, 267-86.
30. Bauer KH, Lehmann K, Osterwald HP, Rothgang G (1998). Coated pharmaceutical dosage forms, Boca Raton, CRC Press, 81-9.
31. Stulzer HK, Segatto Silva MA, Fernandes D, Assreuy J (2008). Development of controlled release captopril granules coated with ethylcellulose and methylcellulose by fluid bed dryer, Drug Del, 15, 11-18.
32. Hu LD, Liu Y, Tang X, Zhang Q (2006). Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets, Eur J Pharm Biopharm, 64, 185-92.
33. Ur-Rahman N, Yuen KH, Wong JW (2006). Diltiazem release from Eudragit NE40 coated pellets and effects of thermal treatment, Saudi Pharm J, 14, 69-74.
34. Kitazawa S, Johno I, Mihouchi T, Okada J (1977). Interpretation of dissolution rate data from in vitro testing of compressed tablets, J Pharm Pharmacol, 29, 453-9.
35. Costa P, Lobo JMS (2000). Modelling and comparison of dissolution profiles, Eur J Pharm Sci, 13, 123-33.
36. Varelas CG, Dixon DG, Steiner C (1995). Zero-order release from biphasic polymer hydrogels, J Contr Rel, 34, 185-92.
37. Gibaldi M, Feldman S (1967). Establishment of sink conditions in dissolution rate determinations, J Pharm Sci, 56, 1238-42.
38. Wagner JG (1969). Interpretation of percent dissolved-time plots derived form in vitro testing of conventional tablets and capsules, J Pharm Sci, 18, 1253-7.
39. Wagner JG (1971). Biopharmaceutics and relevant pharmacokinetics, Hamilton, IL, Drug Intelligence Publications, 120.
40. Higuchi T (1961). Rate of release of medicaments from ointment bases containing drugs in suspensions, J Pharm Sci, 50, 874-5.
41. Hixson AW, Crowell JH (1931). Dependence of reaction velocity upon surface and agitation. I. Theoretical consideration, Ind Eng Chem, 23, 923-31.
42. Niebergall PJ, Milosovich G, Goyan JE (1963). Dissolution rate studies. II. Dissolution of particles under conditions of rapid agitation, J Pharm Sci, 52, 236-41.
43. Korsemeyer RW, Peppas NA (1983). Macromolecular and modeling aspects of swelling-controlled systems. In, Mansdorf SZ, Roseman TJ, eds. Controlled Release Delivery Systems, New York, Marcel Dekker, 77.
44. Siepmann J, Peppas NA (2001). Modelling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC), Adv Drug Deliv Rev, 48, 139-57.
45. Yuskel N, Kanik AE, Baykara T (2000). Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods, Int J Pharm, 209, 56-67.